Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-2.03% $15.94
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 878.74 mill |
EPS: | 0.630 |
P/E: | 25.30 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 117.86 mill |
Avg Daily Volume: | 1.511 mill |
RATING 2024-03-28 |
---|
A+ |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 25.30 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
4.30x |
Company: PE 25.30 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 15.25 - 16.63 ( +/- 4.35%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Elsbernd Brian | Sell | 25 000 | Common stock, par value $0.001 per share |
2024-02-15 | Del Carmen Jeffrey | Sell | 10 667 | Restricted Stock Units |
2024-02-15 | Del Carmen Jeffrey | Buy | 10 667 | Common stock, par value $0.001 per share |
2024-02-15 | Del Carmen Jeffrey | Sell | 3 125 | Common stock, par value $0.001 per share |
2024-02-15 | Daly Richard J | Sell | 4 000 | Restricted Stock Units |
INSIDER POWER |
---|
38.45 |
Last 100 transactions |
Buy: 3 301 722 | Sell: 1 453 545 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $15.94 (-2.03% ) |
Volume | 1.124 mill |
Avg. Vol. | 1.511 mill |
% of Avg. Vol | 74.40 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.41 | N/A | Active |
---|
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.